UAE's Strategic Roadmap Aims To Advance Alzheimer’s Disease Care And Management

A recent report by The Economist Impact, commissioned by Eli Lilly, highlights the UAE's initiatives in managing Alzheimer's disease. It also suggests steps to enhance its global healthcare standing. Alzheimer's is the most prevalent form of dementia, affecting over 55 million people worldwide. The UAE has implemented proactive measures to address this growing issue, considering longer lifespans and an aging population.

Efforts by the Ministry of Health and Prevention (MoHAP) and organisations like 4-get-me-not have been pivotal. In 2015, Sharjah was recognised as the first Arab Age Friendly City in the Middle East by WHO, setting a benchmark for healthy aging practices. These initiatives demonstrate the UAE's commitment to tackling Alzheimer's disease effectively.

The report recommends focusing on three key areas to bolster the UAE’s healthcare infrastructure and policies. Firstly, developing a national plan for Alzheimer’s disease involving diverse stakeholders can guide a coordinated response. This includes government bodies, industry experts, academia, patients, and caregivers working together.

Secondly, enhancing training for healthcare professionals is crucial. Primary care providers often serve as initial contacts for Alzheimer's patients. Upskilling them can facilitate early diagnosis and interventions, improving patient outcomes significantly.

Investing in public education is another critical area highlighted in the report. Addressing stigma and misconceptions about Alzheimer’s disease can ensure people recognise early signs and know where to seek support. This awareness is vital for timely intervention and better management of the condition.

Roberta Marinelli, Eli Lilly President and General Manager for Middle East and Türkiye, stated: "Breakthroughs in science are transforming how we detect and treat Alzheimer’s disease, enabling more efficient care. However, realising the full impact of these advancements depends on strategic collaboration to ensure they reach patients effectively."

Strategic Collaboration

Lilly has been at the forefront of Alzheimer’s research for 35 years. Marinelli emphasised that progress accelerates when there is collective action: "By partnering with the UAE’s healthcare community, we are determined to set benchmarks that not only transform care locally but also shape global practice." Such collaborations are essential for advancing treatment methods.

The report titled "Changing the Narrative: Alzheimer’s Disease in the UAE" was unveiled at the 5th Abu Dhabi Brain Conference. This event brought together international neuroscience leaders to foster innovation in brain health. The focus on Alzheimer’s signifies a strategic push towards policy change and integrated care models.

This comprehensive report offers an evidence-based roadmap for strengthening healthcare leadership in the UAE. It aims to redefine how nations respond to Alzheimer’s disease by promoting dialogue on policy change and innovation within integrated care frameworks.

With inputs from WAM